NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences will present expanded Phase 2 SAVITRI study data for osavampator, a first-in-class AMPA receptor modulator for major depressive disorder, at Psych Congress 2025.

The NHS in England has approved relugolix combination therapy as the first long-term daily oral treatment for endometriosis, expected to benefit around 1,000 women annually whose symptoms persist despite previous treatments.

Neurocrine Biosciences initiated Phase 1 trials for NBIP-01435, a long-acting injectable CRF1 receptor antagonist for congenital adrenal hyperplasia (CAH), complementing its recently approved oral therapy CRENESSITY.

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

Draig Therapeutics launched with $140 million in Series A funding to develop next-generation treatments for neuropsychiatric disorders, marking the largest commercial investment in Welsh research to date.

AbbVie has filed a new patent infringement lawsuit against Hetero Labs to prevent the production of generic versions of its endometriosis drug Orilissa (elagolix sodium).

Voyager Therapeutics published the first peer-reviewed study demonstrating alkaline phosphatase (ALPL) receptor's ability to transport novel AAV capsids across the blood-brain barrier in Molecular Therapy.

Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.

Phase 3 CAHtalyst pediatric study demonstrates that crinecerfont (CRENESSITY) effectively reduces glucocorticoid dosing while maintaining or improving androstenedione levels in children with classic congenital adrenal hyperplasia.

New analyses from Neurocrine Biosciences' Phase 3 CAHtalyst Pediatric study demonstrate CRENESSITY (crinecerfont) consistently reduced glucocorticoid doses while maintaining or improving androstenedione levels across all patient subgroups.